Trial Profile
A 48 Week, Phase II, Open-Label, 2-Cohort, Multicenter Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of GW433908 and GW433908/RTV When Administered to HIV-1 Infected Protease Inhibitor (PI) Naive and PI-Experienced Pediatric Subjects Aged 4 Weeks to greater than 2 Years.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Fosamprenavir (Primary) ; Ritonavir
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors ViiV Healthcare
- 09 Oct 2023 Status changed from active, no longer recruiting to completed.
- 04 Jun 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Nov 2016)
- 08 May 2014 Planned End Date changed from 1 Jul 2015 to 1 Jun 2021 as reported by ClinicalTrials.gov.